Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FUCA1 | P04066 | 2/20 | 0.55 |
| ▸ | ACHE | P22303 | 1/20 | 0.55 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.50 |
| ▸ | MLNR | O43193 | 1/20 | 0.50 |
| ▸ | MC4R | P32245 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | HTR2A | P28223 | 1/20 | 0.47 |
| ▸ | HTR2C | P28335 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | HTR2B | P41595 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3324661 | 1.00 | FUCA1 (0.55) | FUCA1ACHESIGMAR1CYP3A4MLNR | |
| SCHEMBL3522692 | 1.00 | FUCA1 (0.55) | FUCA1ACHESIGMAR1CYP3A4MLNR | |
| SCHEMBL4279682 | 1.00 | FUCA1 (0.55) | FUCA1ACHESIGMAR1CYP3A4MLNR | |
| SCHEMBL3495257 | 0.87 | FUCA1 (0.46) | FUCA1ACHESIGMAR1CYP3A4MLNR | |
| SCHEMBL25097092 | 0.85 | FUCA1 (0.45) | FUCA1ACHESIGMAR1CYP3A4MLNR | |
| SCHEMBL29257047 | 0.85 | FUCA1 (0.45) | FUCA1ACHESIGMAR1CYP3A4MLNR | |
| SCHEMBL29257048 | 0.85 | FUCA1 (0.45) | FUCA1ACHESIGMAR1CYP3A4MLNR | |
| SCHEMBL30419036 | 0.84 | S1PR5 (0.52) | FUCA1ACHECYP3A4MLNRS1PR1 | |
| SCHEMBL13232099 | 0.83 | ACHE (0.58) | ACHESIGMAR1MEN1ALDH1A1KMT2A | |
| SCHEMBL31495661 | 0.83 | FUCA1 (0.43) | FUCA1ACHESIGMAR1CYP3A4MLNR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12441731-B2 | Pyrazolopyrimidine compounds and uses thereof | INCYTE CORPORATION (US) | 2025-10-14 | — | — | US | disclosed |
| EP-3856348-B1 | PYRAZOLO[4,3-D]PYRIMIDINE COMPOUNDS AS ALK2 AND/OR FGFR MODULATORS | INCYTE CORP (US) | 2024-01-03 | — | — | EP | disclosed |
| US-20220017521-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF | INCYTE CORPORATION | 2022-01-20 | — | — | US | disclosed |
| US-11111247-B2 | Pyrazolopyrimidine compounds and uses thereof | INCYTE CORPORATION (US) | 2021-09-07 | — | — | US | disclosed |
| US-20200095250-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF | INCYTE CORPORATION | 2020-03-26 | — | — | US | disclosed |
| US-7772227-B2 | Tricyclic 1-[(indol-3-yl)carbonyl]piperazine derivatives as cannabinoid CB1 receptor agonists | N.V. ORGANON (NL) | 2010-08-10 | — | — | US | disclosed |
| US-7534794-B2 | Certain arylaliphatic and heteroaryl-aliphatic piperazinyl pyrazines and their use in the treatment of serotonin-related diseases | BIOVITRUM AB (SE) | 2009-05-19 | — | — | US | disclosed |
| EP-1343775-B1 | PIPERAZINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2008-06-04 | — | — | EP | disclosed |
| US-20070088025-A1 | such as (R)-3-Cyclohexyl-2,3-dihydro-6-(4-ethylpiperazin-1-ylcarbonyl)pyrrolo[1,2,3-de]-1,4-benzoxazine hydrochloride salt, used as analgesics for the treatment of post-operative pain, chronic pain neuropathic pain, cancer pain and spasticity associated with multiple sclerosis | AKZO NOBEL N.V. (NL) | 2007-04-19 | — | — | US | disclosed |
| EP-1696930-B1 | TRICYCLIC 1-((3-INDOL-3-YL)CARBONYL)PIPERAZINE DERIVATIVES AS CANNABINOID CB1 RECEPTOR AGONISTS | ORGANON NV (NL) | 2007-04-11 | — | — | EP | disclosed |
| US-20030092694-A1 | Certain arylaliphatic and heteroaryl-aliphatic piperazinyl pyrazines and their use in the treatment of serotonin-related diseases | BIOVITRUM, AB, A STOCKHOLM, SWEDEN CORPORATION | 2003-05-15 | — | — | US | disclosed |
| US-20030065179-A1 | Sorbitol dehydrogenase inhibitors | CHU-MOYER MARGARET Y (US) | 2003-04-03 | — | — | US | disclosed |
| US-20030013721-A1 | Novel piperidine and piperazine derivatives | ASTRAZENECA AB (SE) | 2003-01-16 | — | — | US | disclosed |
| US-6465467-B1 | DISEASES RELATED TO THE 5-HT2C RECEPTOR, ESPECIALLY EATING, MEMORY, MOOD, URINARY AND ANXIETY DISORDERS, SCHIZOPHRENIA, PAIN, SEXUAL DYSFUNCTIONS | BIOVITRUM AB (SE) | 2002-10-15 | — | — | US | disclosed |
| EP-1242427-A1 | NOVEL PIPERIDINE AND PIPERAZINE DERIVATIVES | AstraZeneca AB (SE) | 2002-09-25 | — | — | EP | disclosed |
| US-6414149-B1 | TREATING DIABETES, TREATING OR PREVENTING DIABETIC COMPLICATIONS | PFIZER INC. | 2002-07-02 | — | — | US | disclosed |
| WO-2002048124-A2 | PIPERAZINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2002-06-20 | — | — | WO | disclosed |
| EP-1185275-A1 | AMINOPYRIMIDINES AS SORBITOL DEHYDROGENASE INHIBITORS | Pfizer Products Inc. (US) | 2002-03-13 | — | — | EP | disclosed |
| WO-2001046200-A1 | NOVEL PIPERIDINE AND PIPERAZINE DERIVATIVES | ASTRAZENECA AB (SE) | 2001-06-28 | — | — | WO | disclosed |
| WO-2000059510-A1 | AMINOPYRIMIDINES AS SORBITOL DEHYDROGENASE INHIBITORS | PFIZER PRODUCTS INC. (US) | 2000-10-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030092694-A1 | Certain arylaliphatic and heteroaryl-aliphatic piperazinyl pyrazines and their use in the treatment of serotonin-related diseases | HTR2C, HTR3C, HTR2A | FUCA1 3404/4885ACHE 1329/4885SIGMAR1 48/4885 |
| US-20200095250-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF | ALK, FGFR1, FGFR2 | FUCA1 2762/4885ACHE 4547/4885SIGMAR1 4726/4885 |
| US-20030013721-A1 | Novel piperidine and piperazine derivatives | IL5, VIP, EP300 | FUCA1 3830/4885ACHE 3691/4885SIGMAR1 124/4885 |
| US-12441731-B2 | Pyrazolopyrimidine compounds and uses thereof | ALK, FGFR1, FGFR2 | FUCA1 2762/4885ACHE 4547/4885SIGMAR1 4726/4885 |
| US-20070088025-A1 | such as (R)-3-Cyclohexyl-2,3-dihydro-6-(4-ethylpiperazin-1-ylcarbonyl)pyrrolo[1,2,3-de]-1,4-benzoxazine hydrochloride salt, used as analgesics for the treatment of post-operative pain, chronic pain neuropathic pain, cancer pain and spasticity associated with multiple sclerosis | OPRD1, OPRK1, OPRM1 | FUCA1 3619/4885ACHE 382/4885SIGMAR1 8/4885 |
| US-20030065179-A1 | Sorbitol dehydrogenase inhibitors | SLC5A1, SORD, SLC5A2 | FUCA1 393/4885ACHE 3550/4885SIGMAR1 2002/4885 |
| US-20220017521-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF | ALK, FGFR1, FGFR2 | FUCA1 2762/4885ACHE 4547/4885SIGMAR1 4726/4885 |
| US-11111247-B2 | Pyrazolopyrimidine compounds and uses thereof | ALK, FGFR1, FGFR2 | FUCA1 2762/4885ACHE 4547/4885SIGMAR1 4726/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.